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a b s t r a c t
Bimolecular ﬂuorescence complementation (BiFC) and western blot analysis demonstrated that CCR5
exists as constitutive homo-oligomers, which was further enhanced by its antagonists such as maraviroc
(MVC) and TAK-779. Staining by monoclonal antibodies recognizing different epitopes of CCR5 revealed
that CCR5 oligomer was structurally different from the monomer. To determine which forms of CCR5 are
well recognized by CCR5-using HIV-1 for the entry, BiFC-positive and -negative cell fractions in CD4-
positive 293T cells were collected by ﬂuorescent-activated cell sorter, and infected with luciferase-
reporter HIV-1 pseudotyped with CCR5-using Envs including R5 and R5X4. R5 and dual-R5 HIV-1
substantially infected BiFC-negative fraction rather than BiFC-positive fraction, indicating the preferential
recognition of monomeric CCR5 by R5 and dual-R5 Envs. Although CCR5 antagonists enhanced
oligomerization of CCR5, MVC-resistant HIV-1 was found to still recognize both MVC-bound and
-unbound forms of monomeric CCR5, suggesting the constrained use of monomeric CCR5 by R5 HIV-1.
& 2013 Elsevier Inc. All rights reserved.
Introduction
Interaction of the outer envelope (Env) glycoprotein gp120 of
human immunodeﬁciency virus type-1 (HIV-1) with CD4 and one
of the coreceptors (either CCR5 or CXCR4) is essential for the entry
of HIV-1 (reviewed in (Wilen et al., 2012)). Viruses that exclusively
use CCR5 (R5 HIV-1) are transmission variants, and predominant
throughout the course of infection. On the other hand, viruses that
use CXCR4 emerge at late stage of infection, and are thought to be
associated with CD4 depletion and disease progression in half of
HIV-1-infected individuals (Connor et al., 1997; Scarlatti et al.,
1997). Most of CXCR4-using viruses still use CCR5 (R5X4 HIV-1)
while several variants exclusively use CXCR4 (X4 HIV-1).
Previous studies have shown that natural ligands such as
macrophage inﬂammatory protein (MIP)-1α (CCL3), MIP-1β
(CCL4), and RANTES (regulated on activation, normal T-cell
expressed and secreted; CCL5) were able to inhibit R5 HIV-1
replication by steric hindrance or internalization of CCR5
(Alkhatib et al., 1997; Cocchi et al., 1995; Oberlin et al., 1996;
Scarlatti et al., 1997). The antagonists of CCR5, such as TAK-779 and
maraviroc (MVC), also interact with hydrophobic pocket of CCR5
formed by the transmembrane helices, and induce conformational
changes in CCR5, thereby blocking entry of R5 HIV-1 (Dragic et al.,
2000; Kondru et al., 2008; Maeda et al., 2006; Nishikawa et al.,
2005; Seibert et al., 2006; Tsamis et al., 2003). The dimerization of
CCR5 induced by anti-CCR5 mAb CCR5-02 was also reported to
prevent the entry of R5 HIV-1 (Vila-Coro et al., 2000), suggesting
the possible impact of dimerization or oligomerization of CCR5 on
HIV-1 susceptibility. Although CCR5 was reported to exist as
homo-oligomers without natural ligands (Benkirane et al., 1997;
El-Asmar et al., 2005; Hammad et al., 2010; Issafras et al., 2002;
Mellado et al., 2001; Sohy et al., 2009), it still remains to be
determined whether oligomeric forms of CCR5 are structurally
different from the monomeric forms, and affect entry efﬁciency of
R5 HIV-1. It is also unknown whether CCR5 antagonists affect the
oligomerization status of CCR5, whereas the CCR5 natural ligands
have been shown to induce the dimerization of CCR5 (Chelli and
Alizon, 2002; Hernanz-Falcon et al., 2004; Rodriguez-Frade et al.,
1999; Vila-Coro et al., 2000). To address these issues, bimolecular
ﬂuorescence complementation (BiFC) assay was applied to detect
homo-oligomeric forms of CCR5. Principally, BiFC assay is a
non-invasive ﬂuorescent-based technique that allows detection
of protein-protein interactions in living cells (reviewed in
(Kerppola, 2008)). BiFC assay is based on the association between
two non-ﬂuorescent fragments of a ﬂuorescent protein when they
are brought in proximity to each other by interaction between
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proteins fused to the fragments. In our present study, by using
BiFC, homo-oligomeric forms of CCR5 were detected to some
extent without natural ligands, and further enhanced by CCR5
antagonists. In addition, susceptibility of sorted CCR5 oligomers-
enriched cell fraction was found to be less susceptible compared to
monomer-enriched fraction, indicating the preferential recogni-
tion of CCR5 monomer by R5 HIV-1.
Results
Detection of oligomeric forms of CCR5 without ligands
It has been shown that CCR5 exists as homo-oligomer without
natural ligands such as CCL3, CCL4, and CCL5 (Benkirane et al.,
1997; El-Asmar et al., 2005; Hammad et al., 2010; Issafras et al.,
2002; Mellado et al., 2001; Sohy et al., 2009). However, it still
remains to be determined whether oligomeric forms of CCR5 are
structurally different from CCR5 monomer. To this end, BiFC assay
was employed to detect oligomeric forms of CCR5. The CCR5
expression vectors fused to the N- and C-terminal fragments of
green ﬂuorescence protein (Kusabira–Green: KG) were con-
structed, and co-expressed in 293T cells. When the both proteins
are expressed and close together, refolded KG protein results in KG
signal. This ﬂuorescent signal can be easily detected by ﬂow
cytometry or ﬂuorescence microscopy. To analyze the structural
differences between monomeric and oligomeric forms of CCR5,
the cells were further stained with anti-CCR5 monoclonal anti-
bodies (mAbs) recognizing different epitopes of CCR5 such as
N-terminal (clones CTC8, 3A9), second extracellular domain (ECL2)
(clones 2D7, 45531), or multiple conformation (clone 45549).
As shown in the upper panel of Fig. 1, we were able to detect
ﬂuorescent (KG) signal using ﬂow cytometry when both CCR5-
KGN and CCR5-KGC were co-expressed in 293T cells, indicating the
oligomerization of CCR5 without ligands. We also noticed that
proportions of CCR5þKGþ subset were almost equal (24–26%) in
all anti-CCR5 mAb clones (CTC8, 3A9, 2D7, and 45531) except the
clone 45549. In contrast, CCR5þKG subset was differentially
stained by anti-CCR5 mAbs (Fig. 1, upper panel). The proportions
of CCR5þKG subset were high in the clones 2D7 and CTC8 (62%
and 55%, respectively), intermediate in the clone 45531 (43%),
and low in the clone 3A9 (26%). These results suggested that
monomeric forms of CCR5 were structurally different from the
oligomeric forms.
Enhancement of CCR5 oligomerization by CCR5 antagonists
Although natural ligands such as CCL3, CCL4, and CCL5 have
been showing to induce oligomerization of CCR5 (Chelli and Alizon,
2002; Hernanz-Falcon et al., 2004; Rodriguez-Frade et al., 1999;
Vila-Coro et al., 2000), it has not been determined how CCR5
antagonists such as TAK-779 or MVC affect the oligomerization of
CCR5. Therefore, we also applied BiFC technique to check the effects
of CCR5 antagonists on the oligomerization status of CCR5. After co-
expressing CCR5-KGN and –KGC in 293T cells in the presence of
MVC, the cells were stained with above-mentioned anti-CCR5
mAbs. The proportions of CCR5þKGþ subset were largely
increased in all anti-CCR5 mAb clones (Fig. 1, lower panel) com-
pared to those of the same fraction in the absence of ligands (Fig. 1,
upper panel). Notably, the proportion of CCR5þKGþ subset was
increased in the clone 45549 though its reactivity was quite low in
the absence of ligands, conﬁrming that conformational changes of
CCR5 were indeed induced by MVC. To verify the enhancement of
CCR5 oligomerization by CCR5 antagonists, we then checked
whether another CCR5 antagonist TAK-779 enhanced oligomeriza-
tion of CCR5. The CCR5-KG-expressing 293T cells were stained with
2D7 mAb that was able to equally detect both CCR5þKG and
CCR5þKGþ subsets as shown in Fig. 1, and KG-positive percentages
in 2D7-positive population were determined by ﬂow cytometry. We
found that TAK-779 also enhanced the oligomerization of CCR5,
while a CXCR4 antagonist AMD3100 had no effect (Fig. 2A). In
particular, MVC had higher activity to enhance CCR5 oligomeriza-
tion than TAK-779 in 293T cells. Western blot analysis using 293T
cells expressing FLAG-tagged CCR5 with cross-linker indicated that
CCR5 largely existed as monomer but also as dimer in the absence
of ligands though lesser extent (Fig. 2B). It was also shown that MVC
was able to induce expression of not only dimer but also more than
dimer forms of CCR5. Notably, the level of CCR5 expression was up-
regulated by MVC though the reason was uncertain. Native-PAGE
analyses also revealed the similar results (Supplementary Fig. S1).
The enhancement by CCR5 antagonists was also observed in
different cell types such as HeLa, and NP2 cell lines though both
had comparable activities in these cell lines (Supplementary
Fig. S2). Dose-escalating study revealed that the concentrations
Fig. 1. Flow cytometry analyses of CCR5-KG-expressing 293T cells by anti-CCR5 mAbs in the presence or absence of MVC. The 293T cells were transfected with both CCR5-KG
expression vectors, and incubated at 37 1C for 48 h in the absence of ligands (upper panel) or the presence of MVC at 2 μM (lower panel). Anti-CCR5 mAbs recognizing
N-terminus (clones CTC8 and 3A9), ECL-2 (clone 2D7, 45531), and multiple domains (clone 45549) were used for the detection of CCR5, and analyzed by ﬂow cytometry. The
y-, and x-axes show the mean ﬂuorescence intensity of CCR5 and KG, respectively. The number of each column shows the percent positive in each region.
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for enhanced oligomerization of CCR5 by TAK-779 or MVC were
indeed corresponded to the inhibitory concentrations against HIV-1
infection (Fig. 2C). For example, in the case of MVC, the EC50 value of
inhibitory activity against R5 HIV-1 (JR-FL) was 3.771.4 nM (data
not shown), while the EC50 value of activity to enhance oligomer-
ization of CCR5 was 7.475.1 nM, indicating that CCR5 could be
oligomerized at enough concentrations for inhibiting R5 HIV-1
infection.
It has been shown that oligomerization of CCR5 was induced
shortly after the addition of natural ligands as previously
described (Chelli and Alizon, 2002; Hernanz-Falcon et al., 2004;
Rodriguez-Frade et al., 1999; Vila-Coro et al., 2000). However, a
time-course experiment showed that more than 24 h were neces-
sary to enhance CCR5 oligomerization by MVC (Fig. 2D). Confocal
laser scanning microscopy also showed that the CCR5-KG signals
were located not only at the plasma membrane but also in the
cytoplasm without ligands, and were further augmented by MVC
(Fig. 2E). These results suggested that oligomerization of CCR5
needed de novo synthesis of CCR5 and occurred in the intracellular
compartments before expressed on the cell surface.
Infection of KG-positive and -negative cell fractions with R5 HIV-1
Since the structures of oligomeric forms of CCR5 were possibly
different frommonomeric CCR5 as shown in Fig. 1, we next analyzed
the abilities of R5 HIV-1 to recognize monomeric and oligomeric
forms of CCR5. To this end, we ﬁrst stained CD4-positive 293T cells
expressing CCR5-KGN and –KGC with anti-CCR5 mAb CTC8, which
was able to recognize both monomeric and oligomeric forms of
CCR5, and had no neutralizing activity against CCR5-using HIV-1
(data not shown). The KG-positive and -negative subsets having the
same CCR5 ﬂuorescent intensity were then collected by ﬂuorescent-
activated cell sorter. The mean ﬂuorescence intensities of KG in KG-
positive and -negative cell fractions after sorting were 30.2 and 4.1,
respectively, while mean ﬂuorescence intensities of CCR5 were
comparable (72.3 and 61.1 respectively) (Fig. 3A). The mean ﬂuor-
escence intensity of CD4 was also conﬁrmed to be comparable in
KG-positive and -negative cell fractions (183 and 178, respectively).
The sorted each cell fraction was then infected with HIV-1 pseudo-
typed with various strains of R5 Envs including JR-FL, YU-2, and
Ba-L. Since the transfection of CD4-293T cells with KG-expressing
vectors was possible to inﬂuence the cell condition, each cell fraction
was also infected with HIV-1 pseudotyped with vesicular stomatitis
virus G protein (VSV-G), which utilizes the ubiquitously expressing
molecule(s) although the receptor for VSV-G remains to be con-
ﬁrmed (Coil and Miller, 2004; Schlegel et al., 1983). To normalize the
entry efﬁciency of R5 HIV-1 in each fraction, we divided luciferase
activities infected with R5 pseudotyped HIV-1 by those infected
with VSV-G pseudotyped HIV-1. The susceptibility of CCR5þKGþ
subset to R5 HIV-1 was then compared with that of CCR5þKG
subset. Although each single cell of CCR5þKG or CCR5þKGþ
subset was supposed to have oligomeric and monomeric forms of
CCR5 to some extent, respectively, we found that entry efﬁciencies of
R5 HIV-1 in CCR5þKGþ subset were always lower than those in
Fig. 2. Enhanced homo-oligomerization of CCR5 by CCR5 antagonists. (A) The 293T cells were transfected with expression vectors of CCR5-KG, and incubated in the presence
or absence of AMD3100, TAK-779 or MVC at 2 μM each. The cells were stained with anti-CCR5 mAb 2D7, and analyzed by ﬂow cytometry. The data shown represent the mean
values of the percentage of KG-positive in 2D7-positive cell fraction7standard deviations of three independent experiments. (B) The 293T cells were transfected with
pCCR5-FLAG in the presence or absence of MVC. The cells were cross-linked by DSP, lysed, and analyzed by Western blot using anti-FLAG mAb. (C) Transfected cells were
treated with increasing concentrations of TAK-779 or MVC ranging from 0.2 nM to 2 μM, and incubated at 37 1C for 48 h. The data shown represent the mean values of
percent positive of KG7standard deviations of three independent experiments. (D) The 293T cells expressing CCR5-KG were incubated at 37 1C for the indicated time of
period in the presence of MVC (1 μM). Results are mean values of CCR5-KG positive rates7standard deviations from experiments performed in triplicate. (E) Transfected
HeLa cells with CCR5-KG were incubated in the absence (upper panel) or presence of MVC (lower panels) at 37 1C for 48 h, and ﬁxed with 4% paraformaldehyde.
Representative images in the middle sections of the cells are shown. Nuclear staining by DAPI is shown in blue. Scale bars correspond to 10 μm.
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CCR5þKG subset (Fig. 3B). These results indicated that R5 Envs
preferentially recognized monomeric forms of CCR5 rather than its
oligomeric forms.
Infection of KG-positive and -negative cell fractions with R5X4 HIV-1
We next checked the susceptibilities of CCR5þKG and
CCR5þKGþ subsets to another CCR5-using HIV-1, R5X4. As we
mentioned earlier, there were several phenotypes in the strains of
R5X4 HIV-1 such as dual-R5 and dual-X4 (Symons et al., 2011;
Toma et al., 2010). We then selected 89.6 as dual-X4, KMT, TIK, and
89.6R308S as dual-R5 as previously described (Maeda et al., 2008).
Similar to R5 HIV-1, dual-R5 preferentially infected CCR5þKG
fraction compared to CCR5þKGþ fraction (Fig. 4). Notably, single
mutation in 11th position of the V3 loop in 89.6 (89.6R308S),
which changed viral phenotype from dual-X4 to dual-R5 (Maeda
et al., 2008), also signiﬁcantly infected CCR5þKG fraction than
CCR5þKGþ fraction. In contrast, wild type 89.6 (dual-X4) com-
parably infected both CCR5þKG and CCR5þKGþ fractions.
These results indicated that dual-R5 but not dual-X4 HIV-1 also
preferentially recognized monomeric CCR5 for the entry.
Infection of CCR5-KG-positive and -negative cell fractions
with
MVC-resistant HIV-1
Since the CCR5 antagonist MVC strongly enhanced CCR5 oligo-
merization in 293T cells as shown in Figs. 1 and 2, MVC-resistant
HIV-1 seemed to evolve to use oligomeric forms of CCR5 for the
entry. In general, MVC-resistant HIV-1s were shown to recognize
MVC-bound form of CCR5 to reduce sensitivity to MVC as previously
described by others and us (Kuhmann et al., 2004; Maeda et al., 2011;
Pugach et al., 2007; Trkola et al., 2002; Westby et al., 2007; Yuan
et al., 2011). We therefore sought to infect CCR5þKG and
CCR5þKGþ fractions with MVC-resistant HIV-1 in the absence or
presence of 2 μM MVC, respectively. Similar to general R5 HIV-1s,
MVC-resistant HIV-1 also preferentially infected CCR5þKG fraction
in both the absence and presence of MVC compared with
CCR5þKGþ fraction (Fig. 5A). We further infected both fractions at
various concentrations of MVC ranging from 100 nM to 10 μM in
order to check whether MVC-resistant HIV-1 recognizes MVC-bound
forms of CCR5. Both fractions were also infected with MVC-sensitive
HIV-1 carrying JR-FL Env to check whether sensitivity of general R5
HIV-1 to MVC is different between them. We found that MVC-
sensitive HIV-1 had reduced sensitivity to MVC in CCR5þKG
fraction compared with CCR5þKGþ fraction (Fig. 5B), supporting
the preferential recognition of CCR5 monomer by CCR5-using Env.
We further observed reduced maximal inhibition of MVC-resistant
HIV-1 in CCR5þKG fraction compared with CCR5þKGþ fraction
(Fig. 5B). These results indicated that MVC-resistant HIV-1 was likely
to use MVC-bound forms of CCR5 monomer though MVC augmented
CCR5 oligomerization.
Discussion
HIV-1 coreceptors CCR5 and CXCR4 are members of the seven
transmembrane (7-TM) G protein-coupled receptors (GPCRs)
superfamily. Recent data have shown that many GPCRs including
chemokine receptors function as dimers or higher-order oligo-
mers. To assess the formation of dimerization/oligomerization of
GPCRs, ﬂuorescent- or bioluminescent-based techniques have
been applied such as BiFC, ﬂuorescence resonance energy transfer
(FRET), bioluminescence resonance energy transfer (BRET) assay
(reviewed in (Vidi et al., 2011)). In the case of BiFC, the expression
vectors for BiFC are generally comprised of two fragments of non-
functional ﬂuorescent protein split by N- and C-terminus (KGN
and KGC of Kusabira–Green: KG in our case). When GPCRs fused to
KGN and KGC are brought in close proximity, ﬂuorescent signal
can be detected by refolding of the ﬂuorescent protein, KG.
It should be noted that KG-signal could be only detected when
KGN and KGC are brought together but not the same pairs such as
KGN–KGN or KGC–KGC. Nonetheless, we were able to show KG-
positive cells in both CCR5-KGN and CCR5-KGC expressing cells
Fig. 3. Sorting of CCR5þKG and CCR5þKGþ fractions and infection with
luciferase-reporter HIV-1 pseudotyped with R5 Envs. (A) CD4-positive 293T cells
expressing CCR5-KG were stained with anti-CCR5 mAb CTC8 (shown in the left
panel). Representative data of ﬂow cytometric analysis is shown. The KG (shown
in black rectangle) and KGþ (shown in gray rectangle) fractions with the same
mean ﬂuorescence intensities of CCR5 were gated, and sorted by ﬂuorescent-
activated cell sorter. Each sorted fraction was analyzed using ﬂow cytometry
(shown in the right panel). (B) Each sorted fraction was infected with luciferase-
reporter HIV-1 pseudotyped with R5 Envs or VSV-G, and luciferase activities of
infected cells were determined 24 h post-infection. Entry efﬁciency of each R5 Env
in each fraction was normalized by that of VSV-G. Relative entry efﬁciency
of CCR5þKGþ fraction (shown in gray bar) was expressed as the percentage of
that of CCR5þKG fraction (shown in white bar). The data are expressed as
means7standard deviations in triplicate experiments.
Fig. 4. Infection of CCR5þKG and CCR5þKGþ fractions with luciferase-reporter
HIV-1 pseudotyped with R5X4 Envs. Sorted CCR5þKG and CCR5þKGþ fractions
were infected with luciferase-reporter HIV-1 pseudotyped with R5X4 Envs or VSV-
G. The luciferase activities of infected cells were determined 24 h post-infection.
Entry efﬁciency of each R5X4 Env in each fraction was normalized by that of VSV-G.
Relative entry efﬁciency of CCR5þKGþ fraction (shown in gray bar) was expressed
as the percentage of that of CCR5þKG fraction (shown in white bar). The data are
expressed as means7standard deviations in triplicate experiments.
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(Fig. 1) without ligands, which were further increased by the CCR5
antagonists but not by the CXCR4 antagonist (Figs. 1 and 2). These
results indicated that CCR5 was able to form dimer/oligomers. It is
well known that CXCR4 exists as constitutive higher order oligo-
mers without natural ligands (Supplementary Fig. S1) (Babcock
et al., 2003; Hamatake et al., 2009; Issafras et al., 2002;
Percherancier et al., 2005; Toth et al., 2004; Wu et al., 2010).
CCR5 could also exist as dimer or higher order oligomers as
recently described (Babcock et al., 2003; Benkirane et al., 1997;
Issafras et al., 2002), although to a lesser extent than CXCR4. On
the present study, we further showed not only the existence of
CCR5 monomer/dimer forms without its ligands but also the
enhanced oligomerization by the antagonists (Fig. 2 and Fig. S1).
It has been shown that natural ligands for CCR5 such as CCL5
(RANTES) or CCL4 (MIP-1β) have been shown to induce homo-
oligomerization of CCR5 (Chelli and Alizon, 2002; Hernanz-Falcon
et al., 2004; Rodriguez-Frade et al., 1999; Vila-Coro et al., 2000),
though its physiological role remains to be determined. Similarly,
CXCR4’s natural ligand SDF-1 also induced homo-dimerization of
CXCR4 as previously described (Percherancier et al., 2005; Toth
et al., 2004; Vila-Coro et al., 1999). In contrast, oligomerization of
chemokine receptors by their antagonists has not been described
to date though another GPCR melatonin receptor was reported to
form dimer by both agonists and antagonists (Ayoub et al., 2002).
The dimerization of melatonin receptor by both agonist and
antagonists was explained by the stabilization of its conforma-
tions. Interestingly, in the presence of MVC, CCR5þKGþ subset
became well detected by the anti-CCR5 mAb recognizing the
conformational epitope (clone 45549) (Fig. 1), indicating that
conformations of CCR5 induced by MVC might be also structurally
stable. In our ﬂow cytometric analyses without addition of ligands,
CCR5þKGþ subsets were equally detected by most anti-CCR5
mAbs except the clone 45549 (Fig. 1). Given that several antigenic
conformations of CCR5 existed on the cell surface (Berro et al.,
2011; Lee et al., 1999), oligomer forms of CCR5 might have the
similar antigenic conformations while monomeric forms had
different antigenic conformations.
Previous reports have shown that several GPCRs were homo- or
hetero-oligomerized in endoplasmic reticulum (ER) (Herrick-Davis
et al., 2006; Issafras et al., 2002; Milligan, 2010; Salahpour et al.,
2004; Vischer et al., 2011). In our BiFC assay using confocal laser
scanning microscopy, CCR5-KG signals were also detected not only
at plasma membrane but also in intracellular compartments, both
of which were further enhanced by the addition of MVC (Fig. 2E).
Time-course experiments also showed that more than 24 h were
needed for the enhanced oligomerization of CCR5 by MVC
(Fig. 2D). These ﬁndings suggested that oligomerization of CCR5
were formed during early biosynthesis and protein maturation in
the ER, and that MVC may further enhance CCR5 oligomerization
by the binding of intracellular CCR5. Thus, it is possible that MVC
could penetrate into the cell membrane and act before the
expression of CCR5 on the cell surface. It is of note that the
concentration to induce oligomerization of CCR5 was sufﬁciently
low similar to the concentration that is able to inhibit R5 HIV-1
replication (Fig. 2C), indicating the concentrations of MVC, which
would be achieved in HIV-1-infected individuals treated with
MVC, seems to induce oligomerization of CCR5 to some extent
in vivo, although the pharmacological and pathological roles of
MVC-induced CCR5 oligomerization in primary T cells and macro-
phages still remains to be determined.
As we mentioned above, it is possible that CCR5 monomer may
have multiple forms, whereas the oligomers may have relatively
ﬁxed forms. Since R5 HIV-1 is supposed to recognize speciﬁc forms
of CCR5 (Berro et al., 2011, 2013), we attempted to check which
form of CCR5, monomer or oligomer, is used by R5 HIV-1. To this
end, CCR5þKG and CCR5þKGþ subsets expressed in CD4-
positive 293T cells were fractionated by ﬂuorescent-activated cell
sorter, and infected with pseudotyped R5 HIV-1. The CCR5þKG
and CCR5þKGþ subsets could have relatively lower and higher
amount of oligomeric forms, respectively, while both CCR5þKG
and CCR5þKGþ subsets are supposed to have monomeric and
oligomeric forms of CCR5 in ﬂow cytometry analysis. Nevertheless,
we were able to show that CCR5þKGþfraction was less susceptible
to R5 and dual-R5 HIV-1 than CCR5þKG fraction (Fig. 3 and 4). It
is thus likely that R5 and dual-R5 Envs preferentially recognized
monomeric forms of CCR5. The dimerization induced by the
monoclonal antibody CCR5-02 was previously reported to cause
blocking of HIV-1 entry (Vila-Coro et al., 2000). Our present study
further clariﬁed that the oligomerization of CCR5 without ligands
also affected the susceptibility to R5 and dual-R5 HIV-1.
Although the susceptibility of KG-negative cell fraction to R5 and
dual-R5 HIV-1 was signiﬁcantly high, dual-X4 HIV-1 89.6 equally
infected both CCR5þKG and CCR5þKGþ fraction (Fig. 4). It is
therefore possible that dual-X4 lost the preferential recognition of
monomeric forms of CCR5, and may commence recognizing homo-
oligomeric forms of CCR5. Intriguingly, the single mutation in 89.6
from arginine to serine at 11th position of the V3 loop (89.6R308S),
which changed the tropism from dual-X4 to dual-R5 (Maeda et al.,
Fig. 5. Infection of CCR5þKG and CCR5þKGþ fractions with luciferase-reporter HIV-1 pseudotyped with JR-FL and MVC-resistant Envs. (A) Sorted CCR5þKG and
CCR5þKGþ fractions were infected with luciferase-reporter HIV-1 pseudotyped with MVC-resistant Env or VSV-G in the absence or presence of 2 μM MVC. The luciferase
activities of infected cells were determined 24 h post-infection. Entry efﬁciencies of MVC-resistant Env in CCR5þKG and CCR5þKGþ fractions in the presence or absence
of MVC were normalized by those of VSV-G, respectively. Relative entry efﬁciency of CCR5þKGþ fraction (shown in gray bar) was expressed as the percentage of that of
CCR5þKG fraction (shown in white bar). (B) Percentages of inhibition of MVC-sensitive (JR-FL) and MVC-resistant HIV-1s are expressed as relative values, with that of
MVC-sensitive HIV-1 in CCR5þKG fractions at 10 μM MVC being 100%. The data are expressed as means7standard deviations in triplicate experiments.
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2008), also reverted to recognize monomeric forms of CCR5. Hence,
the single amino acid substitution was sufﬁcient to lose preferential
recognition of monomer forms of CCR5 for CCR5-using HIV-1.
As described by others and us, MVC-resistant HIV-1 recognized
MVC-bound and -unbound forms of CCR5 (Kuhmann et al., 2004;
Maeda et al., 2011; Pugach et al., 2007; Trkola et al., 2002; Westby
et al., 2007; Yuan et al., 2011). Since MVC was found to enhance
CCR5 oligomerization in our present study, we then sought to
check whether MVC-resistant HIV-1 recognizes MVC-bound forms
of CCR5 oligomers. However, similar to R5 HIV-1, we found that
MVC-resistant HIV-1 recognized both MVC-bound and -unbound
forms of CCR5 monomer (Fig. 5). Since numbers of MVC-bound
forms of CCR5 monomer would be dependent on the surface
expression levels of CCR5 and cell types, our ﬁndings may partly
explain why susceptibility to CCR5 antagonists was dependent on
the cell types as previously described (Berro et al., 2011). Taken
together, it is likely that R5 HIV-1 including MVC-resistant HIV-1
constrained to use monomeric forms of CCR5 for the entry.
In conclusion, we were able to show that oligomeric forms of
CCR5 were less susceptible to R5 HIV-1 than the monomeric
forms. However, our ﬁndings were obtained from the cells
expressing high levels of CCR5 in vitro. Therefore, it is quite
important to understand the role of CCR5 oligomerization in
primary T cells and macrophages for HIV-1 entry in vivo. The
methods to detect native forms of homo- and hetero-oligomerized
CCR5 and their susceptibilities to HIV-1 in primary cells should be
established and analyzed to elucidate the role of CCR5 oligomer-
ization for HIV-1 infection in vivo.
Materials and methods
Cells and culture conditions
The 293T and HeLa cells were maintained in Dulbecco0s modiﬁed
Eagle medium (DMEM) (Sigma-Aldrich) supplemented with 10% fetal
bovine serum (FBS) (Gibco BRL), 100 U/ml of penicillin and 100 μg/ml
of streptomycin. A human CD4-expressing glioma cell line (NP2/CD4)
was maintained in Eagle0s minimum essential medium (MEM; Gibco
BRL) supplemented with 10% FBS, 100 U/ml of penicillin and 100 μg/
ml of streptomycin (Jinno et al., 1998).
Coreceptor antagonists
A CXCR4 antagonist AMD3100 (Schols et al., 1997a, 1997b) and
a CCR5 antagonist maraviroc (MVC) (Dorr et al., 2005) were
supplied by the AIDS Research and Reference Reagent Program,
Division of AIDS, National Institute of Allergy and Infectious
Diseases. A CCR5 antagonist TAK-779 (Baba et al., 1999) was kindly
obtained from Takeda Chemical Industries (Osaka, Japan).
Construction of retrovirus vector and transduction of 293T cells
with the CD4 gene
The cDNA encoding human CD4 was obtained by PCR using
human lymphocyte cDNA as the template. The primers used were
as follows: 50-CTCGAGTCGCCACCATGAACCGGGGAGTCCCTTTTAGC-
30 and 50-TCAAATGGGGCTACATGTCTTCTGAAACCG-30 (underlined
are XhoI site). The ampliﬁed product was cloned into pCR-TOPO
(Invitrogen), and the sequence was veriﬁed using 3130 Genetic
Analyzer (Applied Biosystems). A CCR5 carrying XhoI-EcoRI frag-
ments was ligated into pMSCVpuro (Clothech) to generate
pMSCVpuro-CD4. Retrovirus vector was produced according to
the manufacturer0s instructions, and 293T cells were then trans-
duced and selected by puromycin (Sigma-Aldrich). The CD4
expression of the transduced 293T cells was veriﬁed by anti-CD4
monoclonal antibody (RPA-T4, eBioscience).
Expression vectors
CCR5 expression vectors for BiFC was constructed using phmKGN-
MN and phmKGC-MN (MBL, Japan) according to the manufacture0s
instructions. Brieﬂy, human CCR5 gene was ampliﬁed using pCR2-
CCR5 as a template (Maeda et al., 2000). Primers used were:
50-CTCGAGGAACAAGATGGATTATCAAGTG-30 and 50-GTCTAGATTACT
TGTCGTCATCGTCTTTGTAGTCCAAGCCCACAGATA-30 (underlined are
XhoI and XbaI restriction enzyme sites, respectively). The ampliﬁed
product was cloned into pCR-TOPO, and the sequence was veriﬁed
using 3130 Genetic Analyzer. The XhoI-XbaI fragment carrying CCR5
gene was then ligated into both phmKGN-MN and phmKGC-MN using
XhoI and XbaI sites to generate pCCR5-KGN and pCCR5-KGC respec-
tively. To construct an expression vector of FLAG-tagged CCR5, CCR5
sequence was ampliﬁed using primer: 50-CTCGAGGAACAAGATGGAT-
TATCAAGTG-30 and 50-GTCTAGATTACTTGTCGTCATCGTCTTTGTAGTC-
CAAGCCCACAGATAT-30 (underlined are the XhoI and XbaI restriction
enzyme sites, respectively). The ampliﬁed product was cloned into
pCR-TOPO, and the sequence was then veriﬁed using a 3130 Genetic
Analyzer. The ampliﬁed fragment was ﬁnally ligated into phmKGC-MN
expression vector (In this vector, split ﬂuorescence protein, Kusabira–
Green: KG, was replaced with FLAG-tag by digestion of the XhoI and
XbaI restriction enzyme sites). Expression vectors for JR-FL, 89.6,
89.6R308S, KMT and TIK Envs were prepared as previously described
(Maeda et al., 2000, 2008). Expression vectors for Ba-L and YU-2 Envs
were kindly supplied by K. Yoshimura (National Institute of Infectious
diseases, Tokyo). An expression vector for MVC-resistant Env was
prepared as previously described (Yuan et al., 2011, 2013).
Production of recombinant luciferase-reporter virus
Recombinant luciferase-reporter virus of pseudotyped with var-
ious HIV-1 Envs or VSV-G were produced by transfection of 293T
cells using the calcium phosphate method (ProFection Mammalian
Transfection System, Promega) as previously described (Maeda et al.,
2000, 2008). The cells culture supernatant was collected 48 h post-
transfection, ﬁltered with 0.45 μm pore-size, and stocked at 80 1C
until use. The p24 Gag in the culture supernatant was measured
using HIV-1 p24 Ag ELISA kit (Zeptometrix) according to man-
ufacture0s instructions.
Detection of the CCR5 expression in KG-positive and -negative
cell population
The 293T cells were transfected with CCR5-KG expression
vectors, pCCR5-KGN and pCCR5-KGC, using calcium phosphate
method, and incubated for 48 h or indicated time of period at
37 1C in the presence or absence of 2 μM of AMD3100, TAK-779 or
MVC. In a dose-escalating study, transfected cells were treated
with various concentrations of MVC (ranging from 0.0002 μM to
2 μM) for 48 h. To detect the CCR5 in CCR5-KG-transfected cells,
the cells were ﬁrst incubated with anti-CCR5 mAbs, 3A9, CTC8,
45531, 45549 (R&D Systems), or 2D7 (BD Pharmingen) for 30 min
at 4 1C. The cells were then stained with β-phycoerythrin-
conjugated anti-mouse IgG antibody (Jackson Immuno Research).
For direct detection of the CCR5 expression in CCR5-KG-
transfected cells, the cells were stained with anti-human CCR5
mAb 2D7 conjugated with Alexa Fluor 647 (BioLegend) for 30 min
at 4 1C. The cells were analyzed by FACScan or FACSCalibur
ﬂuorescent-activated cell sorter (Becton Dickinson).
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Detection of monomeric and oligomeric forms of CCR5
by Western blot
The transfected 293T cells with pCCR5-FLAG expression vector
were incubated at 37 1C for 48 h with or without MVC. The cells
were treated with DSP (dithiobis[succinimidylpropionate]) cross-
linker according to the manufacture0s instructions (Thermo Scien-
tiﬁc), and solubilized using 1% Brij O10 (Sigma-Aldrich) lysis buffer
(1% Brij O10, 20 mM Tris–HCl pH 8.2, 0.15 M NaCl, 5 mM iodoace-
tamide) including protease inhibitor cocktail (Sigma-Aldrich).
The cell lysates were then separated by SDS-PAGE, blotted onto
PVDF (polyvinylidene ﬂuoride, Immobilon-P, Millipore) mem-
brane. The membranes were incubated with anti-FLAG mAb
(Wako) or anti-β-actin mAb (Sigma-Aldrich) for 90 min, followed
by staining with horseradish peroxidase (HRP)-conjugated anti-
mouse IgG (Jackson Immuno Research). The signals were detected
using Chemi-Lumi One (Nacalai Tesque).
Confocal laser scanning microscopy
The HeLa cells were plated to collagen (Atelo Cell)-coated
8-well glass slides (Lab-Tek). The cells were transfected with both
pCCR5-KGN and pCCR5-KGC using Lipofectamine 2000 (Invitro-
gen) according to the manufacture0s instructions. Transfected cells
were incubated at 37 1C for 48 h in the presence or absence of
1 μMMVC. The cells were ﬁxed with 4% paraformaldehyde (Wako)
for 15 min, and analyzed using LSM-700-ZEN confocal laser scan-
ning microscopy (Carl Zeiss) with a 60X objective lens. The images
were processed using LSM Imaging Browser (Carl Zeiss).
Fluorescence-activated cell sorting of CCR5-KG-positive and -negative
cell fraction and infection with pseudotyped HIV-1
The CD4-293T cells were transfected with pCCR5-KGN and
pCCR5-KGC using calcium phosphate method. After 48 h cultures
at 37 1C, cells were stained with anti-CCR5 mAb CTC8, followed by
staining with APC-conjugated anti-mouse IgG. The cells were then
sorted into CCR5þKG and CCR5þKGþ fractions with the same
expression levels of CCR5 by using FACS AriaII (Becton Dickinson)
according to the manufacture0s instructions. Sorted each fraction
was then incubated with the same amount (40 ng of p24Ag) of
luciferase-reporter HIV-1 pseudotyped with various HIV-1 Envs
including R5 (JR-FL, YU-2, Ba-L), R5X4 (89.6 wt, 89.6 R308S
(Maeda et al., 2008), KMT, and TIK), MVC-resistant Env (T199K/
T275M/V3-M5) (Yuan et al., 2011, 2013) or VSV-G at 37 1C for
30 min to allow adsorption of the virus. The cells were washed to
remove unadsorbed virus, seeded into a 96-well plate, and
cultured at 37 1C for 24 h. Luciferase activity was measured using
a luminometer, Lumat LB 9501/16 (EG&G Berthold, Bad Wildbad).
The entry efﬁciency of HIV-1 infected by HIV-1 Envs in each cell
fraction was normalized by the luciferase activity of the same
fraction infected by VSV-G.
Acknowledgments
We thank Dr. Kazuhisa Yoshimura and Takeda Chemical Indus-
tries for providing Env expression vectors of YU-2 and Ba-L, and
TAK-779, respectively. Thanks are also due to Dr. Kazuhisa Yoshi-
mura and Dr. Shuzo Matsushita for helpful discussions. This work
was supported by Grants-in-Aid for Scientiﬁc Research, and the
Global COE program “Global Education and Research Center
Aiming at the control of AIDS” supported by the Ministry of
Education, Science, Sports, and Culture of Japan; by a Grant-in-
Aid for scientiﬁc research from the Ministry of Health of Japan.
Appendix A. Supplementary material
Supplementary data associated with this article can be found in
the online version at http://dx.doi.org/10.1016/j.virol.2013.12.034.
References
Alkhatib, G., Locati, M., Kennedy, P.E., Murphy, P.M., Berger, E.A., 1997. HIV-1
coreceptor activity of CCR5 and its inhibition by chemokines: independence
from G protein signaling and importance of coreceptor downmodulation.
Virology 234, 340–348.
Ayoub, M.A., Couturier, C., Lucas-Meunier, E., Angers, S., Fossier, P., Bouvier, M.,
Jockers, R., 2002. Monitoring of ligand-independent dimerization and ligand-
induced conformational changes of melatonin receptors in living cells by
bioluminescence resonance energy transfer. J. Biol. Chem. 277, 21522–21528.
Baba, M., Nishimura, O., Kanzaki, N., Okamoto, M., Sawada, H., Iizawa, Y., Shiraishi,
M., Aramaki, Y., Okonogi, K., Ogawa, Y., Meguro, K., Fujino, M., 1999. A small-
molecule, nonpeptide CCR5 antagonist with highly potent and selective anti-
HIV-1 activity. Proc. Nat. Acad. Sci. U.S.A. 96, 5698–5703.
Babcock, G.J., Farzan, M., Sodroski, J., 2003. Ligand-independent dimerization of
CXCR4, a principal HIV-1 coreceptor. J. Biol. Chem. 278, 3378–3385.
Benkirane, M., Jin, D.-Y., Chun, R.F., Koup, R.A., Jeang, K.-T., 1997. Mechanism of
transdominant inhibition of CCR5-mediated HIV-1 infection by ccr5Δ32. J. Biol.
Chem. 272, 30603–30606.
Berro, R., Klasse, P.J., Lascano, D., Flegler, A., Nagashima, K.A., Sanders, R.W., Sakmar,
T.P., Hope, T.J., Moore, J.P., 2011. Multiple CCR5 conformations on the cell
surface are used differentially by human immunodeﬁciency viruses resistant or
sensitive to CCR5 inhibitors. J. Virol. 85, 8227–8240.
Berro, R., Yasmeen, A., Abrol, R., Trzaskowski, B., Abi-Habib, S., Grunbeck, A.,
Lascano, D., Goddard, W.A., Klasse, P.J., Sakmar, T.P., Moore, J.P., 2013. Use of
G-protein-coupled and -uncoupled CCR5 receptors by CCR5 inhibitor-resistant
and -sensitive human immunodeﬁciency virus type 1 variants. J. Virol. 87,
6569–6581.
Chelli, M., Alizon, M., 2002. Rescue of HIV-1 receptor function through cooperation
between different forms of the CCR5 chemokine receptor. J. Biol. Chem. 277,
39388–39396.
Cocchi, F., DeVico, A.L., Garzino-Demo, A., Arya, S.K., Gallo, R.C., Lusso, P., 1995.
Identiﬁcation of RANTES, MIP-1 alpha, and MIP-1 beta as the major HIV-
suppressive factors produced by CD8þ T cells. Science 270, 1811–1815.
Coil, D.A., Miller, A.D., 2004. Phosphatidylserine is not the cell surface receptor for
vesicular stomatitis virus. J. Virol. 78, 10920–10926.
Connor, R.I., Sheridan, K.E., Ceradini, D., Choe, S., Landau, N.R., 1997. Change in
coreceptor use correlates with disease progression in HIV-1-infected indivi-
duals. J. Exp. Med. 185, 621–628.
Dorr, P., Westby, M., Dobbs, S., Grifﬁn, P., Irvine, B., Macartney, M., Mori, J., Rickett, G.,
Smith-Burchnell, C., Napier, C., Webster, R., Armour, D., Price, D., Stammen, B.,
Wood, A., Perros, M., 2005. Maraviroc (UK-r27,857), a potent, orally bioavailable,
and selective small-molecule inhibitor of chemokine receptor CCR5 with broad-
spectrum anti-human immunodeﬁciency virus type 1 activity. Antimicrob. Agents
Chemother. 49, 4721–4732.
Dragic, T., Trkola, A., Thompson, D.A., Cormier, E.G., Kajumo, F.A., Maxwell, E., Lin, S.W.,
Ying, W., Smith, S.O., Sakmar, T.P., Moore, J.P., 2000. A binding pocket for a small
molecule inhibitor of HIV-1 entry within the transmembrane helices of CCR5. Proc.
Nat. Acad. Sci. U.S.A. 97, 5639–5644.
El-Asmar, L., Springael, J.Y., Ballet, S., Andrieu, E.U., Vassart, G., Parmentier, M.,
2005. Evidence for negative binding cooperativity within CCR5-CCR2b hetero-
dimers. Mol. Pharmacol. 67, 460–469.
Hamatake, M., Aoki, T., Futahashi, Y., Urano, E., Yamamoto, N., Komano, J., 2009.
Ligand-independent higher-order multimerization of CXCR4, a G-protein-
coupled chemokine receptor involved in targeted metastasis. Cancer Sci. 100,
95–102.
Hammad, M.M., Kuang, Y.Q., Yan, R., Allen, H., Dupre, D.J., 2010. Naþ/Hþ exchanger
regulatory factor-1 is involved in chemokine receptor homodimer CCR5
internalization and signal transduction but does not affect CXCR4 homodimer
or CXCR4–CCR5 heterodimer. J. Biol. Chem. 285, 34653–34664.
Hernanz-Falcon, P., Rodriguez-Frade, J.M., Serrano, A., Juan, D., del Sol, A., Soriano, S.
F., Roncal, F., Gomez, L., Valencia, A., Martinez-A, C., Mellado, M., 2004.
Identiﬁcation of amino acid residues crucial for chemokine receptor dimeriza-
tion. Nat. Immunol. 5, 216–223.
Herrick-Davis, K., Weaver, B.A., Grinde, E., Mazurkiewicz, J.E., 2006. Serotonin
5-HT2C receptor homodimer biogenesis in the endoplasmic reticulum: real-
time visualization with confocal ﬂuorescence resonance energy transfer. J. Biol.
Chem. 281, 27109–27116.
Issafras, H., Angers, S., Bulenger, S., Blanpain, C., Parmentier, M., Labbé-Jullié, C.,
Bouvier, M., Marullo, S., 2002. Constitutive agonist-independent CCR5 oligo-
merization and antibody-mediated clustering occurring at physiological levels
of receptors. J. Biol. Chem. 277, 34666–34673.
Jinno, A., Shimizu, N., Soda, Y., Haraguchi, Y., Kitamura, T., Hoshino, H., 1998.
Identiﬁcation of the chemokine receptor TER1/CCR8 expressed in brain-derived
cells and T cells as a new coreceptor for HIV-1 infection. Biochem. Biophys. Res.
Commun. 243, 497–502.
Kerppola, T.K., 2008. Bimolecular ﬂuorescence complementation (BiFC) analysis as
a probe of protein interactions in living cells. Annu. Rev. Biophys. 37, 465–487.
Y. Nakano et al. / Virology 452-453 (2014) 117–124 123
Kondru, R., Zhang, J., Ji, C., Mirzadegan, T., Rotstein, D., Sankuratri, S., Dioszegi, M.,
2008. Molecular interactions of CCR5 with major classes of small-molecule
anti-HIV CCR5 antagonists. Mol. Pharmacol. 73, 789–800.
Kuhmann, S.E., Pugach, P., Kunstman, K.J., Taylor, J., Stanﬁeld, R.L., Snyder, A., Strizki,
J.M., Riley, J., Baroudy, B.M., Wilson, I.A., Korber, B.T., Wolinsky, S.M., Moore, J.P.,
2004. Genetic and phenotypic analyses of human immunodeﬁciency virus type
1 escape from a small-molecule CCR5 Inhibitor. J. Virol. 78, 2790–2807.
Lee, B., Sharron, M., Blanpain, C., Doranz, B.J., Vakili, J., Setoh, P., Berg, E., Liu, G., Guy,
H.R., Durell, S.R., Parmentier, M., Chang, C.N., Price, K., Tsang, M., Doms, R.W.,
1999. Epitope mapping of CCR5 reveals multiple conformational states and
distinct but overlapping structures involved in chemokine and coreceptor
function. J. Biol. Chem. 274, 9617–9626.
Maeda, K., Das, D., Ogata-Aoki, H., Nakata, H., Miyakawa, T., Tojo, Y., Norman, R.,
Takaoka, Y., Ding, J., Arnold, G.F., Arnold, E., Mitsuya, H., 2006. Structural and
molecular interactions of CCR5 inhibitors with CCR5. J. Biol. Chem. 281,
12688–12698.
Maeda, Y., Foda, M., Matsushita, S., Harada, S., 2000. Involvement of both the V2 and
V3 regions of the CCR5-tropic human immunodeﬁciency virus type 1 envelope
in reduced sensitivity to macrophage inﬂammatory protein 1α. J. Virol. 74,
1787–1793.
Maeda, Y., Yoshimura, K., Miyamoto, F., Kodama, E., Harada, S., Yuan, Y., Harada, S.,
Yusa, K., 2011. In vitro and In vivo resistance to human immunodeﬁciency virus
type 1 entry inhibitors. AIDS Clin. Res., S2.
Maeda, Y., Yusa, K., Harada, S., 2008. Altered sensitivity of an R5X4 HIV-1 strain 89.6
to coreceptor inhibitors by a single amino acid substitution in the V3 region of
gp120. Antiviral Res. 77, 128–135.
Mellado, M., Rodriguez-Frade, J.M., Vila-Coro, A.J., Fernandez, S., Martin de Ana, A.,
Jones, D.R., Toran, J.L., Martinez-A, C., 2001. Chemokine receptor homo- or
heterodimerization activates distinct signaling pathways. EMBO J. 20,
2497–2507.
Milligan, G., 2010. The role of dimerisation in the cellular trafﬁcking of G-protein-
coupled receptors. Curr. Opin. Pharmacol. 10, 23–29.
Nishikawa, M., Takashima, K., Nishi, T., Furuta, R.A., Kanzaki, N., Yamamoto, Y.,
Fujisawa, J.-i., 2005. Analysis of binding sites for the new small-molecule CCR5
antagonist TAK-220 on human CCR5. Antimicrob. Agents Chemother. 49,
4708–4715.
Oberlin, E., Amara, A., Bachelerie, F., Bessia, C., Virelizier, J.L., Arenzana-Seisdedos, F.,
Schwartz, O., Heard, J.M., Clark-Lewis, I., Legler, D.F., Loetscher, M., Baggiolini,
M., Moser, B., 1996. The CXC chemokine SDF-1 is the ligand for LESTR/fusin and
prevents infection by T-cell-line-adapted HIV-1. Nature 382, 833–835.
Percherancier, Y., Berchiche, Y.A., Slight, I., Volkmer-Engert, R., Tamamura, H., Fujii,
N., Bouvier, M., Heveker, N., 2005. Bioluminescence resonance energy transfer
reveals ligand-induced conformational changes in CXCR4 homo- and hetero-
dimers. J. Biol. Chem. 280, 9895–9903.
Pugach, P., Marozsan, A.J., Ketas, T.J., Landes, E.L., Moore, J.P., Kuhmann, S.E., 2007.
HIV-1 clones resistant to a small molecule CCR5 inhibitor use the inhibitor-
bound form of CCR5 for entry. Virology 361, 212–228.
Rodriguez-Frade, J.M., Vila-Coro, A.J., Martin, A., Nieto, M., Sanchez-Madrid, F.,
Proudfoot, A.E., Wells, T.N., Martinez, A.C., Mellado, M., 1999. Similarities and
differences in RANTES- and (AOP)-RANTES-triggered signals: implications for
chemotaxis. J. Cell Biol. 144, 755–765.
Salahpour, A., Angers, S., Mercier, J.-F., Lagacé, M., Marullo, S., Bouvier, M., 2004.
Homodimerization of the β2-adrenergic receptor as a prerequisite for cell
surface targeting. J. Biol. Chem. 279, 33390–33397.
Scarlatti, G., Tresoldi, E., Bjorndal, A., Fredriksson, R., Colognesi, C., Deng, H.K.,
Malnati, M.S., Plebani, A., Siccardi, A.G., Littman, D.R., Fenyo, E.M., Lusso, P.,
1997. In vivo evolution of HIV-1 co-receptor usage and sensitivity to
chemokine-mediated suppression. Nat. Med. 3, 1259–1265.
Schlegel, R., Tralka, T.S., Willingham, M.C., Pastan, I., 1983. Inhibition of VSV binding
and infectivity by phosphatidylserine: is phosphatidylserine a VSV-binding
site? Cell 32, 639–646.
Schols, D., Este, J.A., Henson, G., De Clercq, E., 1997a. Bicyclams, a class of potent
anti-HIV agents, are targeted at the HIV coreceptor fusin/CXCR-4. Antiviral Res.
35, 147–156.
Schols, D., Struyf, S., Van Damme, J., Este, J.A., Henson, G., De Clercq, E., 1997b.
Inhibition of T-tropic HIV strains by selective antagonization of the chemokine
receptor CXCR4. J. Exp. Med. 186, 1383–1388.
Seibert, C., Ying, W., Gavrilov, S., Tsamis, F., Kuhmann, S.E., Palani, A., Tagat, J.R.,
Clader, J.W., McCombie, S.W., Baroudy, B.M., Smith, S.O., Dragic, T., Moore, J.P.,
Sakmar, T.P., 2006. Interaction of small molecule inhibitors of HIV-1 entry with
CCR5. Virology 349, 41–54.
Sohy, D., Yano, H., de Nadai, P., Urizar, E., Guillabert, A., Javitch, J.A., Parmentier, M.,
Springael, J.-Y., 2009. Hetero-oligomerization of CCR2, CCR5, and CXCR4 and the
protean effects of “selective” antagonists. J. Biol. Chem. 284, 31270–31279.
Symons, J., van Lelyveld, S.F., Hoepelman, A.I., van Ham, P.M., de Jong, D., Wensing,
A.M., Nijhuis, M., 2011. Maraviroc is able to inhibit dual-R5 viruses in a dual/
mixed HIV-1-infected patient. J. Antimicrob. Chemother. 66, 890–895.
Toma, J., Whitcomb, J.M., Petropoulos, C.J., Huang, W., 2010. Dual-tropic HIV type
1 isolates vary dramatically in their utilization of CCR5 and CXCR4 coreceptors.
AIDS 24, 2181–2186.
Toth, P.T., Ren, D., Miller, R.J., 2004. Regulation of CXCR4 receptor dimerization by
the chemokine SDF-1alpha and the HIV-1 coat protein gp120: a ﬂuorescence
resonance energy transfer (FRET) study. J. Pharmacol. Exp. Ther. 310, 8–17.
Trkola, A., Kuhmann, S.E., Strizki, J.M., Maxwell, E., Ketas, T., Morgan, T., Pugach, P.,
Xu, S., Wojcik, L., Tagat, J., Palani, A., Shapiro, S., Clader, J.W., McCombie, S.,
Reyes, G.R., Baroudy, B.M., Moore, J.P., 2002. HIV-1 escape from a small
molecule, CCR5-speciﬁc entry inhibitor does not involve CXCR4 use. Proc.
Nat. Acad. Sci. U.S.A. 99, 395–400.
Tsamis, F., Gavrilov, S., Kajumo, F., Seibert, C., Kuhmann, S., Ketas, T., Trkola, A.,
Palani, A., Clader, J.W., Tagat, J.R., McCombie, S., Baroudy, B., Moore, J.P., Sakmar,
T.P., Dragic, T., 2003. Analysis of the mechanism by which the small-molecule
CCR5 antagonists SCH-351125 and SCH-350581 inhibit human immunodeﬁ-
ciency virus type 1 entry. J. Virol. 77, 5201–5208.
Vidi, P.-A., Ejendal, K.F.K., Przybyla, J.A., Watts, V.J., 2011. Fluorescent protein
complementation assays: new tools to study G protein-coupled receptor
oligomerization and GPCR-mediated signaling. Mol. Cell. Endocrinol. 331,
185–193.
Vila-Coro, A.J., Mellado, M., Martín de Ana, A., Lucas, P., del Real, G., Martínez-A., C.,
Rodríguez-Frade, J.M, 2000. HIV-1 infection through the CCR5 receptor is
blocked by receptor dimerization. Proc. Nat. Acad. Sci. U.S.A. 97, 3388–3393.
Vila-Coro, A.J., Rodriguez-Frade, J.M., Martin De Ana, A., Moreno-Ortiz, M.C.,
Martinez, A.C., Mellado, M., 1999. The chemokine SDF-1alpha triggers CXCR4
receptor dimerization and activates the JAK/STAT pathway. FASEB J. 13,
1699–1710.
Vischer, H.F., Watts, A.O., Nijmeijer, S., Leurs, R., 2011. G protein-coupled receptors:
walking hand-in-hand, talking hand-in-hand? Br. J. Pharmacol. 163, 246–260.
Westby, M., Smith-Burchnell, C., Mori, J., Lewis, M., Mosley, M., Stockdale, M., Dorr, P.,
Ciaramella, G., Perros, M., 2007. Reduced maximal inhibition in phenotypic
susceptibility assays indicates that viral strains resistant to the CCR5 antagonist
maraviroc utilize inhibitor-bound receptor for entry. J. Virol. 81, 2359–2371.
Wilen, C.B., Tilton, J.C., Doms, R.W., 2012. HIV: cell binding and entry. Cold Spring
Harb. Perspect. Med., 2.
Wu, B., Chien, E.Y.T., Mol, C.D., Fenalti, G., Liu, W., Katritch, V., Abagyan, R., Brooun, A.,
Wells, P., Bi, F.C., Hamel, D.J., Kuhn, P., Handel, T.M., Cherezov, V., Stevens, R.C., 2010.
Structures of the CXCR4 chemokine GPCR with small-molecule and cyclic peptide
antagonists. Science 330, 1066–1071.
Yuan, Y., Maeda, Y., Terasawa, H., Monde, K., Harada, S., Yusa, K., 2011.
A combination of polymorphic mutations in V3 loop of HIV-1 gp120 can confer
noncompetitive resistance to maraviroc. Virology 413, 293–299.
Yuan, Y., Yokoyama, M., Maeda, Y., Terasawa, H., Harada, S., Sato, H., Yusa, K., 2013.
Structure and dynamics of the gp120 V3 loop that confers noncompetitive
resistance in R5 HIV-1JR-FL to maraviroc. PLoS One 8, e65115.
Y. Nakano et al. / Virology 452-453 (2014) 117–124124
